Propeller Health announced that the Food and Drug Administration (FDA) has given clearance to market its Propeller platform for use with drugs using GlaxoSmithKline’s Diskus dry powder inhaler device for asthma and chronic obstructive pulmonary disease (COPD) following its clearance for use with drugs using Boehringer Ingelheim’s Respimat inhaler for COPD.
Propeller is a digital health platform intended to help patients and physicians better understand asthma and COPD, and help improve the outcomes of these conditions. Propeller remotely monitors the use of inhaled rescue and controller medications, analyzes patient trends, and provides routine feedback through its sensor technology, software, and services. Its FDA-approved claims include: increase adherence to therapy, predict oncoming exacerbations, help reduce the frequency of symptoms and exacerbations in asthma and COPD.
In July 2012, Propeller Health received FDA clearance to market the System to patients with chronic respiratory disease for medications using pressurized metered-dose inhalers (MDI). With the new clearance, the Propeller system can now be used with the following medications:
- Spiriva Respimat
- Combivent Respimat
- Striverdi Respimat
- Stiolto Respimat
- Advair Diskus
- Flovent Diskus
- Serevent Diskus
For more information call (877) 251-5451 or visit PropellerHealth.com.